{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-24-000031","form_type":"8-K","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.073171+00:00","generated_at":"2026-06-02T05:15:14.746111+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Supernus to present interim Phase IIa data for SPN-817 on May 23","bullets":["Interim data from open-label Phase IIa study of SPN-817 for treatment-resistant seizures to be reviewed at webcast on May 23, 2024.","Webcast at 4:30 p.m. ET; replay and slides available for 60 days via company website.","No actual clinical results disclosed in this filing; full data release scheduled for the event."],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-24-000031","json":"https://secwatch.observer/filing/0001356576-24-000031.json","markdown":"https://secwatch.observer/filing/0001356576-24-000031.md","text":"https://secwatch.observer/filing/0001356576-24-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657624000031/0001356576-24-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657624000031/supn-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:15:14.746111+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}